ThermoGenesis (THMO) Short-Term Debt to Capital

ThermoGenesis (THMO) develops high-tech instruments for biomaterial analysis. The business relies on stable demand for biobank consumables, which ensures crisis resilience. However, the company faces fierce competition and bureaucratic hurdles during the certification of new products. The technical condition of the plants ensures uninterrupted production, and the metric stands at 5.04. This price chart confirms these fundamental indicators.

This ratio compares the volume of short-term credit obligations to the amount of equity to assess the liquidity and financial stability of assets. Given the rising demand for biobank automation for ThermoGenesis, this balance is critical; therefore, analyzing the structure of short-term liabilities relative to equity allows an investor to determine whether the debt load restricts the scaling of production for stem cell processing systems.